Loading...
XNAS
RPRX
Market cap17bUSD
Dec 05, Last price  
39.73USD
1D
1.48%
1Q
10.15%
IPO
-18.27%
Name

Royalty Pharma PLC

Chart & Performance

D1W1MN
XNAS:RPRX chart
P/E
20.08
P/S
7.62
EPS
1.98
Div Yield, %
1.59%
Shrs. gr., 5y
10.18%
Rev. gr., 5y
4.52%
Revenues
2.26b
-3.86%
1,652,420,0001,877,410,0001,597,930,0001,794,894,0001,814,254,0002,122,000,0002,289,463,0002,237,215,0002,354,554,0002,263,576,000
Net income
859m
-24.31%
581,426,000565,907,0001,210,025,0001,377,729,0002,348,535,000495,198,000478,754,00042,832,0001,134,834,000858,983,000
CFO
2.77b
-7.32%
1,418,313,0001,618,317,0001,667,239,0002,034,629,0002,017,536,0002,143,980,0002,987,802,0002,768,986,000
Dividend
Aug 16, 20240.21 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
IPO date
Jun 16, 2020
Employees
Domiciled in
US
Incorporated in
GB

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT